Return to Clinical Trials Search Results

A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Primary Objective: * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of death from coronary heart disease, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral). Secondary Objective: * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of cardiovascular death, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral). * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of cardiovascular death, MI, or ischemic stroke. * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of MI or death due to coronary heart disease. * To evaluate the efficacy of MK-0616 compared with placebo in increasing the time to cardiovascular death.

Primary Objective: * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of death from coronary heart disease, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral). Secondary Objective: * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of cardiovascular death, MI, ischemic stroke, acute limb ischemia or major amputation, or urgent arterial revascularization (coronary, cerebrovascular, or peripheral). * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of cardiovascular death, MI, or ischemic stroke. * To evaluate the efficacy of MK-0616 compared with placebo on increasing the time to the first event of MI or death due to coronary heart disease. * To evaluate the efficacy of MK-0616 compared with placebo in increasing the time to cardiovascular death.